Business
Regen BioPharma Restructures Management Stock Compensation
Regen BioPharma Restructures Management Stock Compensation.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma Restructures Management Stock Compensation\n\n\n\n\n\nRegen BioPharma Restructures Management Stock Compensation\nCompany cancels 31.5 million shares previously issued to the Management team, replacing them with non-trading Series M Preferred shares with terms tied to achievements\nPR Newswire\nSAN DIEGO, March 15, 2017\n\n\n\nSAN DIEGO, March 15, 2017 /PRNewswire/ --\n\nRegen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) announced that its management team has agreed to collectively cancel 16,500,000 common shares and 15,000,000 Series A Preferred shares. Of these amounts, 7,500,000 common shares and 2,500,000 Series A Preferred shares were already cancelled in December 2016 with the remaining shares being submitted for cancellation on March 13, 2017.\n\nThe Company has created a new class of stock, Series M Preferred which does not trade publicly. The management team will receive replacement shares for the publicly traded shares they cancelled. The Company's Chairman & CEO David Koos said \"The Regen BioPharma Inc. management team collectively feel shifting our employment shares to Series M Preferred makes a huge statement on our commitment to and confidence in the long term growth of Regen. Our motivation and focus is long term shareholder value which we have just memorialized by accepting non-trading Series M Preferred stock for our publicly traded shares.\"\n\nThe Company believes this move will strengthen its relationship with its shareholders, as the compensation incentives for management are tied to achieving milestones.\n\nAbout Regen BioPharma Inc.:  \n\nRegen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.\n\nDisclaimer: This news announcement may contain forward-looking statements. Forward-looking statements ...